Finanzen von Tactile Systems Technology Inc (TCMD)TCMDTactile Systems Technology Inc

Tactile Systems Technology, Inc. (TCMD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Lymphedema products, accounting for 85.9% of total sales, equivalent to $73.63M. Another important revenue stream is Airway clearance products. Understanding this composition is critical for investors evaluating how TCMD navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Tactile Systems Technology, Inc. maintains a gross margin of 75.50%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 7.97%, while the net margin is 9.08%. These profitability ratios, combined with a Return on Equity (ROE) of 11.88%, provide a clear picture of how effectively TCMD converts its operational activities into shareholder value.

In the context of the broader market, TCMD competes directly with industry leaders such as CERS and NPCE. With a market capitalization of $548.19M, it holds a leading position in the sector. When comparing efficiency, TCMD's gross margin of 75.50% stands against CERS's 55.91% and NPCE's 82.83%. Such benchmarking helps identify whether Tactile Systems Technology, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a total revenue of $85.7 million for Q2 2026, reflecting a 9% year-over-year increase, and has a gross margin of 76.3%.